Faeth Therapeutics, Inc.
PublicFaeth Therapeutics, Inc. is now publicly traded
The data on this page reflects Faeth Therapeutics, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Feb 17, 2026
Est. Valuation at Exit
$368.32M
Total Funding Raised
$292M
Company Overview
Faeth Therapeutics, Inc. operates in Biotech and is based in Austin, Texas. It has raised $292M.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company that develops precision therapies and nutritional interventions for cancer treatment.
Sector
Biotech
Verticals
Life Sciences, Oncology
AI Layer
Infrastructure
Faeth Therapeutics, Inc. Comparables
Compare Faeth Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Polaris Group | 77% | |
| StageZero Life Sciences Ltd. | 73% | |
| ImmunoMet Therapeutics | 71% |
For institutional investors. Book with your work email.
Faeth Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Feb 17, 2026 | ||||
| VC Round | Oct 20, 2025 | ||||
| Series A | Jun 30, 2022 | ||||
| Seed | Jan 18, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Faeth Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Balyasny Asset Management L.P. | PIPE |
| RA Capital Management | PIPE |
| Future Ventures | Series A, VC Round, Seed |
| Columbia Threadneedle Investments | PIPE |
| Fairmount Funds Management | PIPE |
| Digitalis Ventures | Series A, VC Round, Seed |
| B Capital Group | VC Round |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 5, 2026
In 2021, Faeth Therapeutics Inc. receives $139M in net proceeds from its public offering at $380 per share, after giving effect to a 1-for-20 reverse stock split in June 2025.
- hiresOct 27, 2026
Faeth Therapeutics Inc. appoints Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of Research and Development at Zymeworks, to its Board of Directors in Texas on Oct 27th '26.
- is_developingSep 18, 2026
Faeth Therapeutics Inc. develops and evaluates FTX-249 preclinically, a selective HPPD inhibitor designed to address limitations associated with nitisinone therapy, on Sep 18th '26.
- is_developingAug 18, 2026
Faeth Therapeutics Inc. is conducting a Phase II trial of Study FTH-PIK-201 in second-line advanced endometrial cancer.
For institutional investors. Book with your work email.
Faeth Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.